Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)

Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)

US Patent 11773182 · Granted Oct 3, 2023

Estimated economic value: $48,904,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherap2025
Methods and related aspects for pathology prognosis2024
Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (2024
PSMA-based molecular-genetic reporter system2024
PSMA-binding agents and uses thereof2024
PSMA targeted fluorescent agents for image guided surgery2024
Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alp2024
Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy2024
Methods and related aspects for pathology prognosis2024
Raman spectroscopy reporters and methods for molecular imaging of tissue in vivo2024
Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibito2023
PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherap2023